Amelioration of rotenone-induced dopaminergic cell death in the striatum by oxytocin treatment

Peptides

Volumn 38, Issue 2, 2012, Pages 312-317

  Erbaş, Oytun ^a   Oltulu, Fatih ^a   Taşkiran, Dilek ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Animal models; Neuroprotection; Oxytocin; Parkinson's disease; Rotenone

Indexed keywords

APOMORPHINE; CASPASE 3; CASPASE 8; OXYTOCIN; PROTEIN BAX; PROTEIN BCL 2; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT; CELL DEATH; CIRCLING BEHAVIOR; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM; WEIGHT;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BODY WEIGHT; CELL DEATH; DOPAMINERGIC NEURONS; MALE; NEOSTRIATUM; OXYTOCIN; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE;

ANIMALIA; RATTUS;

EID: 84868690535     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2012.05.026     Document Type: Article

References (45)

1. M. Alam, and W.J. Schmidt Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats Behav Brain Res 136 2002 317 324
2. S. Authier, J.F. Tanguay, P. Geoffroy, D. Gauvin, S. Bichot, and N. Ybarra Cardiovascular effects of oxytocin infusion in a porcine model of myocardial infarct J Cardiovasc Pharmacol 55 2010 74 82
3. J. Bakos, V. Strbak, N. Ratulovska, and Z. Bacova Effect of oxytocin on neuroblastoma cell viability and growth Cell Mol Neurobiol 32 2012 891 896
4. W.A. Banks, and A.J. Kastin Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine Peptides 15 1994 23 29
5. R. Betarbet, T.B. Sherer, and J.T. Greenamyre Animal models of Parkinson' s disease Bioessays 24 2002 308 318
6. N.K. Biyikli, H. Tugtepe, G. Sener, A. Velioglu-Ogunc, S. Cetinel, and S. Midillioglu Oxytocin alleviates oxidative renal injury in pyelonephritic rats via a neutrophil-dependent mechanism Peptides 27 2006 2249 2257
7. J.R. Cannon, V. Tapias, H.M. Na, A.S. Honick, R.E. Drolet, and J.T. Greenamyre A highly reproducible rotenone model of Parkinson's disease Neurobiol Dis 34 2009 279 290
8. J.R. Cannon, and J.T. Greenamyre The role of environmental exposures in neurodegeneration and neurodegenerative diseases Toxicol Sci 124 2011 225 250
9. M. Ceanga, A. Spataru, and A. Zagrean Oxytocin is neuroprotective against oxygen-glucose deprivation and reoxygenation in immature hippocampal cultures Neurosci Lett 477 2010 15 18
10. J. Chen, and G. Aguilera Vasopressin protects hippocampal neurons in culture against nutrient deprivation or glutamate-induced apoptosis J Neuroendocrinol 22 2010 1072 1081
11. S. Chiu, Y.W. Wong, Y.P. Wan, P. Chiu, and R.K. Mishra Are the pharmacological effects of l-prolyl-l-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms Prog Neuropsychopharmacol Biol Psychiatry 7 1983 739 742
12. M.C. Dery, and E. Asselin Oxytocin upregulates COX-2 and BCL-XL expression through the PI 3-K/Akt signaling pathway Proc Am Assoc Cancer Res 47 2006 4253
13. C.E. Detillion, T.K. Craft, E.R. Glasper, B.J. Prendergast, and A.C. DeVries Social facilitation of wound healing Psychoneuroendocrinology 29 2004 1004 1011
14. D.C. German, K. Manaye, W.K. Smith, D.J. Woodward, and C.B. Saper Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization Ann Neurol 26 1989 507 514
15. G. Gimpl, and F. Fahrenholz The oxytocin receptor system: structure, function, and regulation Physio Rev 81 2011 630 668
16. J.T. Greenamyre, R. Betarbet, and T.B. Sherer The rotenone model of Parkinson's disease: genes, environment and mitochondria Parkinsonism Relat Disord 9 2003 59 64
17. J. Gutkowska, and M. Jankowski Oxytocin: old hormone, new drug Pharmaceuticals 2 2009 168 183
18. S.O. Iseri, G. Sener, B. Saglam, N. Gedik, F. Ercan, and B.C. Yegen Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils J Surg Res 126 2005 73 81
19. P. Jenner Functional models of Parkinson's disease: a valuable tool in the development of novel therapies Ann Neurol 64 2008 16 29
20. F. Jin, Q. Wu, Y.F. Lu, Q.H. Gong, and J.S. Shi Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats Eur J Pharmacol 14 600 2008 78 82
21. R.S. Khan, C. Yu, A.J. Kastin, Y. He, R.H. Ehrensing, and H. Hsuchou Brain activation by peptide Pro-Leu-Gly-NH2 (MIF-1) Int J Peptides 2010 10.1155/2010/537639
22. H. Kobayashi, S. Yasuda, N. Bao, M. Iwasa, I. Kawamura, and Y. Yamada Post-infarct treatment with oxytocin improves function and remodeling via activating cell survival signals and angiogenesis J Cardiovasc Pharmacol 54 2009 510 519
23. B. Leuner, J.M. Caponiti, and E. Gould Oxytocin stimulates adult neurogenesis even under conditions of stress and elevated glucocorticoids Hippocampus 22 2012 861 868
24. N. Li, K. Ragheb, G. Lawler, J. Sturgis, B. Rajwa, and J.A. Melendez Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production J Biol Chem 278 2003 8516 8525
25. S.Y. Lim, S.H. Fox, and A.E. Lang Overview of the extranigral aspects of Parkinson disease Arch Neurol 66 2009 167 172
26. E.R. Marcotte, A. Chugh, R.K. Mishra, and R.L. Johnson Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1) Peptides 19 1998 403 406
27. K. Newhouse, S.L. Hsuan, S.H. Chang, B. Cai, Y. Wang, and Z. Xia Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells Toxicol Sci 79 2004 137 146
28. M. Orth, and A.H. Schapira Mitochondrial involvement in Parkinson's disease Neurochem Int 40 2002 533 541
29. W. Pan, and A.J. Kastin From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptides Peptides 2007 2411 2434
30. G. Paxinos, and C. Watson The Rat Brain: in Stereotaxic Coordinates 4th ed. 1998 Academic Press San Diego, CA
31. M. Petersson, T. Lundeberg, A. Sohlstrom, U. Wiberg, and K. Uvnas-Moberg Oxytocin increases the survival of musculocutaneous flaps Naunyn Schmiedebergs Arch Pharmacol 357 1998 701 704
32. M. Petersson, U. Wiberg, T. Lundeberg, and K. Uvnas-Moberg Oxytocin decreases carrageenan induced inflammation in rats Peptides 22 2001 1479 1484
33. M. Petersson, A. Lagumdzija, A. Stark, and E. Bucht Oxytocin stimulates proliferation of human osteoblast-like cells Peptides 23 2002 1121 1126
34. M. Petersson, and K. Uvnas-Moberg Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels Physiol Behav 83 2004 475 481
35. L.A. Rashed, R.M. Hashem, and H.M. Soliman Oxytocin inhibits NADPH oxidase and P38-MAPK in cisplatin-induced nephrotoxicity Biomed Pharmacother 65 2011 474 480
36. T.B. Sherer, R. Betarbet, C.M. Testa, B.B. Seo, J.R. Richardson, and J.H. Kim Mechanism of toxicity in rotenone models of Parkinson's disease J Neurosci 23 2003 10756 10764
37. A. Strunecka, S. Hynie, and V. Klenerova Role of oxytocin/oxytocin receptor system in regulation of cell growth and neoplastic processes Folia Biologica (Praha) 55 2009 159 165
38. A. Szeto, D.A. Nation, A.J. Mendez, J. Dominguez-Bendala, L.G. Brooks, and N. Schneiderman Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells Am J Physiol Endocrinol Metab 295 2008 1495 1501
39. R. Tamma, G. Colaianni, L.L. Zhu, A. DiBenedetto, G. Greco, and G. Montemurro Oxytocin is an anabolic bone hormone Proc Natl Acad Sci USA 106 2009 7149 7154
40. R.M. Torack, and J.C. Morris Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease J Neural Transm Park Dis Dement Sect 4 1992 165 171
41. H. Tuǧtepe, G. Sener, N.K. Biyikli, M. Yüksel, S. Cetinel, and N. Gedik The protective effect of oxytocin on renal ischemia/reperfusion injury in rats Regul Peptides 140 2007 101 108
42. G.R. Uhl, J.C. Hedreen, and D.L. Price Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions Neurology 35 1985 1215 1218
43. N. Xiong, J. Huang, Z. Zhang, Z. Zhang, J. Xiong, and X. Liu Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease Plos One 18 4 2009 e7878
44. J. Xu, S. Wang, Y. Lin, L. Cao, and Z. Wang Chi Ghrelin protects against cell death of hippocampal neurons in pilocarpine-induced seizures in rats Neurosci. Lett. 453 2009 58 61
45. P. Vernier, F. Moret, S. Callier, M. Snapyan, C. Wersinger, and A. Sidhu The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system Ann N Y Acad Sci 1035 2004 231 249